Company profile for Tempero Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. At Tempero Bio, we’re focused on advancing transformative therapies...
Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. At Tempero Bio, we’re focused on advancing transformative therapies that treat and prevent substance use disorders and recover lives.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1111 Broadway #1300 Oakland, CA 94607
Telephone
Telephone
+1 (510) 227-2102
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/tempero-calls-time-alcohol-use-disorder-while-mulling-options-according-partner

FIERCE BIOTECH
03 Nov 2025

https://www.prnewswire.com/news-releases/tempero-bio-secures-70-million-series-b-financing-to-advance-tmp-301-into-phase-2-trials-for-substance-use-disorders-302408403.html

PR NEWSWIRE
24 Mar 2025

https://www.prnewswire.com/news-releases/tempero-bio-announces-fda-clearance-of-investigational-new-drug-ind-application-for-tmp-301-for-the-treatment-of-alcohol-and-other-substance-use-disorders-301712859.html

PR NEWSWIRE
04 Jan 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty